Breaking Finance News

Arbutus Biopharma Corp (NASDAQ:ABUS) target price raised to $7.00, reported today by William Blair

Arbutus Biopharma Corp (NASDAQ:ABUS) had its target price bumped up to $7 by William Blair in an issued report issued 8/19/2016. The latest target price indicates a potential upside of 0.78% from the company’s most recent closing price.

Displaying a price of $3.94, Arbutus Biopharma Corp (NASDAQ:ABUS) traded 0.26% lower on the day. With the last close down 6.73% from the 200-day moving average, compared to the S&P 500 Index which has decreased -0.01% over the same period. ABUS has been tracking to a 50-day moving average of $3.87 and 200-day average of $4.05. 52,939 shares of the stock exchanged hands, down from ann average volume of 129,352

See Chart Below:

Arbutus Biopharma Corp (NASDAQ:ABUS)

Arbutus Biopharma Corp has a 52 week low of $2.72 and a 52 week high of $7.72 and has a total market value of $0.0.

A total of 5 brokerages have released a research note on the stock. Two firms rate the stock a strong buy, three firms rate the company a buy, 0 firms rate the stock a hold, 0 rate the stock to underperform, and finally 0 analystsrate the stock as sell with an average target price of $13.80

Brief Synopsis About Arbutus Biopharma Corp (NASDAQ:ABUS)

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV). It is developing a pipeline focused on advancing Ribo Nucleic Acid interference therapeutics (RNAi) using its Lipid Nanoparticle technology. The Company’s lead RNAi HBV candidate, ARB-1467, eliminates HBV surface antigen expression in patients chronically infected with HBV. ARB-1467 is being developed as a multi-component RNAi therapeutic that targets various sites on the HBV genome. It is also developing small molecule covalently closed circular deoxyribonucleic acid (cccDNA) formation inhibitors, multiple small molecule orally bioavailable inhibitors of HBV surface antigen production and secretion, and cccDNA epigenetic modifiers and stimulator of interferon genes agonists.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.